Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Debt / NOTE 3.500% 9/1
-
Market price (% of par)
-
158.27%
-
Total 13F principal
-
$199,820,000
-
Principal change
-
+$1,913,000
-
Total reported market value
-
$315,544,975
-
Number of holders
-
17
-
Value change
-
+$5,454,309
-
Number of buys
-
7
-
Number of sells
-
13
Institutional Holders of APELLIS PHARMACEUTICALS INC - NOTE 3.500% 9/1 as of Q1 2022
As of 31 Mar 2022,
APELLIS PHARMACEUTICALS INC - NOTE 3.500% 9/1 was held by
17 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$199,820,000
in principal (par value) of the bond.
The largest 10 bondholders included
WOLVERINE ASSET MANAGEMENT LLC, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), DeepCurrents Investment Group LLC, UBS ASSET MANAGEMENT AMERICAS INC, LAZARD ASSET MANAGEMENT LLC, WELLS FARGO & COMPANY/MN, Verition Fund Management LLC, WELLINGTON MANAGEMENT GROUP LLP, Point72 Asset Management, L.P., and SILVERBACK ASSET MANAGEMENT LLC.
This page lists
17
institutional bondholders reporting positions
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.